RBMY, a novel inhibitor of glycogen synthase kinase 3beta, increases tumor stemness and predicts poor prognosis of hepatocellular carcinoma.

Please use this identifier to cite or link to this item: http://ir.sinica.edu.tw/handle/201000000A/27439

Title:	RBMY, a novel inhibitor of glycogen synthase kinase 3beta, increases tumor stemness and predicts poor prognosis of hepatocellular carcinoma.
Authors:	Chua, HH Tsuei, DJ Lee, PH Jeng, YM Lu, J Wu, JF Su, DS Chen, YH Chien, CS Kao, PC Lee, CN Hu, RH Ni, YH Chang, MH
Issue Date:	2015
Relation:	Hepatology 62(5), 1480-1496
URI:	http://ir.sinica.edu.tw/handle/201000000A/27439
ISSN:	http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=Drexel&SrcApp=hagerty_opac&KeyRecord=0270-9139&DestApp=JCR&RQ=IF_CAT_BOXPLOT
URL:	http://www.ncbi.nlm.nih.gov/pubmed/26185016
Appears in Collections:	基因體研究中心

Show full item record

Last Week
0

Last month
0

checked on Jun 12, 2025

Check